JPRN-UMIN000004215已完成2 期
Safety and Efficacy Study of Sorafenib in Japanese Child-Pugh A and B Patients with Advanced Hepatocellular Carcinoma - Safety and Efficacy Study of Sorafenib in Japanese patients with Advanced Hepatocellular Carcinoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Second primary malignancy 2)Severe cardiac complication 3)Active infection 4)HIV infection 5)Encephalopacy 6)Gastro-esophazeal varices requiring preventive treatment 7)Uncontrolled massive ascitis
研究者
相似试验
招募中
不适用
Evaluation of the safety and efficacy of sorafenib therapy after TACE for unresectable hepatocellular carcinoma (multicenter study)Hepatocellular carcinomaJPRN-UMIN000006475Kagoshima University Medical and Dental Hospital70
尚未招募
不适用
Efficacy and Safety of Sorafenib in Previously treated Advanced Hepatocellular Carcinoma: SOPT studyNeoplasmsKCT0006739ational Cancer Center50
已完成
1 期
A clinical study on safety and efficacy of sorafenib as maintenance chemotherapy after percutaneous isolated hepatic perfusion chemotherapy (PIHP) for advanced hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000008689Department of hepato-biliary-pancreatic surgery, Kobe University30
进行中（未招募）
1 期
Open-label study of surufatinib in Japanese patientsJPRN-jRCT2031210310ITOIGAWA Suguru37
进行中（未招募）
1 期
An exploratory study of sorafenib for patients listed for transplantation due to HCCPatients >18 years with hepatocellular carcinoma, on waiting list for liver transplantationMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentMedDRA version: 12.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableEUCTR2010-024306-36-SEVästra Götalandsregionen21